LLY

764

+2.13%↑

JNJ

176.45

-0.55%↓

ABBV

216.08

-0.77%↓

UNH

339.82

-2.33%↓

AZN

77.61

-0.58%↓

LLY

764

+2.13%↑

JNJ

176.45

-0.55%↓

ABBV

216.08

-0.77%↓

UNH

339.82

-2.33%↓

AZN

77.61

-0.58%↓

LLY

764

+2.13%↑

JNJ

176.45

-0.55%↓

ABBV

216.08

-0.77%↓

UNH

339.82

-2.33%↓

AZN

77.61

-0.58%↓

LLY

764

+2.13%↑

JNJ

176.45

-0.55%↓

ABBV

216.08

-0.77%↓

UNH

339.82

-2.33%↓

AZN

77.61

-0.58%↓

LLY

764

+2.13%↑

JNJ

176.45

-0.55%↓

ABBV

216.08

-0.77%↓

UNH

339.82

-2.33%↓

AZN

77.61

-0.58%↓

Search

Compugen Ltd

Uždarymo kaina

1.36 -2.16

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

1.26

Max

1.38

Pagrindiniai rodikliai

By Trading Economics

Pajamos

-161K

-7.3M

Pardavimai

-1M

1.3M

P/E

Sektoriaus vid.

60.333

35.664

Pelno marža

-584.089

Darbuotojai

74

EBITDA

1M

-7.4M

Rekomendacijos

By TipRanks

Rekomendacijos

Pirkti

12 mėnesių prognozė

+534.33% upside

Dividendai

By Dow Jones

Kitas uždarbis

2025-11-11

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

-8.5M

130M

Ankstesnė atidarymo kaina

3.52

Ankstesnė uždarymo kaina

1.36

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Very Strong Bearish Evidence

Compugen Ltd Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2025-09-16 17:03; UTC

Pagrindinės rinkos jėgos

BrainsWay Shares Rise on FDA Clearance of Major Depressive Disorder Treatment

2025-09-16 16:49; UTC

Pagrindinės rinkos jėgos
Įsigijimai, susijungimai, perėmimai

GD Culture Shares Drop After Deal for Pallas Capital

2025-09-16 16:11; UTC

Pagrindinės rinkos jėgos

Corbus Shares Rise on FDA Fast-Track Designation for Cancer Drug

2025-09-16 23:40; UTC

Rinkos pokalbiai

Nikkei May Decline as Yen Strengthens -- Market Talk

2025-09-16 23:34; UTC

Rinkos pokalbiai

Gold Edges Higher Ahead of FOMC Decision -- Market Talk

2025-09-16 23:20; UTC

Rinkos pokalbiai

Restaurant Brands NZ Can Outperform When Cycle Turns -- Market Talk

2025-09-16 21:10; UTC

Įsigijimai, susijungimai, perėmimai

U.S. Investors, Trump Close In on TikTok Deal With China -- WSJ

2025-09-16 20:51; UTC

Rinkos pokalbiai

U.S. Home Sales, New Home Listings Fall in August -- Market Talk

2025-09-16 20:50; UTC

Rinkos pokalbiai

Energy & Utilities Roundup: Market Talk

2025-09-16 20:50; UTC

Rinkos pokalbiai
Įsigijimai, susijungimai, perėmimai

Basic Materials Roundup: Market Talk

2025-09-16 20:25; UTC

Uždarbis

The AI Trade Has Stocks Near Highs Again. Some Tech Names Remain on the Sidelines -- Barrons.com

2025-09-16 20:24; UTC

Uždarbis

These Stocks Moved the Most Today: Oracle, Tesla, Alphabet, Dave & Buster's, Chipotle, and More -- Barrons.com

2025-09-16 19:19; UTC

Rinkos pokalbiai

U.S. Natural Gas Futures Extend Winning Streak -- Market Talk

2025-09-16 18:52; UTC

Rinkos pokalbiai

Oil Futures Advance on Russia Concerns, Weak Dollar -- Market Talk

2025-09-16 18:44; UTC

Rinkos pokalbiai

Global Equities Roundup: Market Talk

2025-09-16 18:44; UTC

Rinkos pokalbiai

EssilorLuxottica Well-Positioned in Growing Smart-Glasses Market -- Market Talk

2025-09-16 18:40; UTC

Įsigijimai, susijungimai, perėmimai

Details Emerge on U.S.-China TikTok Deal -- WSJ

2025-09-16 18:38; UTC

Rinkos pokalbiai

Meta Seen With Long-Term Opportunity to Lead in Smart Glasses -- Market Talk

2025-09-16 18:19; UTC

Rinkos pokalbiai

Gold Settles at New High Ahead of Fed Decision -- Market Talk

2025-09-16 18:01; UTC

Rinkos pokalbiai

U.S. Dollar Weakness Supports Oil's Gains -- Market Talk

2025-09-16 17:34; UTC

Rinkos pokalbiai

Any Question the Bank of Canada Will Cut Now Look to Have Vanished -- Market Talk

2025-09-16 16:53; UTC

Uždarbis

Software Companies Are Fighting Back With AI. The Stocks Are Still Hurting. -- Barrons.com

2025-09-16 16:20; UTC

Rinkos pokalbiai
Įsigijimai, susijungimai, perėmimai

Basic Materials Roundup: Market Talk

2025-09-16 16:15; UTC

Rinkos pokalbiai
Įsigijimai, susijungimai, perėmimai

Global Commodities Roundup: Market Talk

2025-09-16 16:09; UTC

Rinkos pokalbiai
Įsigijimai, susijungimai, perėmimai

Global Energy Roundup: Market Talk

2025-09-16 16:09; UTC

Rinkos pokalbiai
Įsigijimai, susijungimai, perėmimai

Canada Industry Minister to Meet Mining CEOs on Merger -- Market Talk

2025-09-16 15:35; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2025-09-16 15:35; UTC

Rinkos pokalbiai

Gold Soars Past $3,700 Ahead of Fed Decision -- Market Talk

2025-09-16 15:22; UTC

Rinkos pokalbiai

More Investors Think Dollar is Overvalued in Latest BofA Survey -- Market Talk

2025-09-16 15:21; UTC

Rinkos pokalbiai

Sterling Considered Most Overvalued in Nearly 10 Years -- Market Talk

Akcijų palyginimas

Kainos pokytis

Compugen Ltd Prognozė

Kainos tikslas

By TipRanks

534.33% į viršų

12 mėnesių prognozė

Vidutinis 8.5 USD  534.33%

Aukščiausias 13 USD

Žemiausias 4 USD

Remiantis 2 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Compugen Ltd kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Pirkti

2 ratings

2

Pirkti

0

Laikyti

0

Parduoti

Techninis įvertinimas

By Trading Central

1.25 / 1.48Palaikymas ir pasipriešinimas

Trumpalaikis periodas

Very Strong Bearish Evidence

Vidutinės trukmės periodas

Very Strong Bearish Evidence

Ilgalaikis periodas

Weak Bearish Evidence

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Compugen Ltd

Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company's immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; COM902, a therapeutic antibody targeting TIGIT, which is in Phase I monotherapy clinical study in patients with advanced malignancies through sequential dose escalations; Bapotulimab, a therapeutic antibody targeting ILDR2 that is in Phase I clinical study in patients with naïve head and neck squamous cell carcinoma; and Rilvegostomig, a novel anti-TIGIT/PD-1 bispecific antibody, which is in Phase II clinical study in patients with advanced or metastatic non-small cell lung cancer. Its therapeutic pipeline also includes early-stage immuno-oncology programs focused to address various mechanisms of immune resistance; and COM503, high affinity antibody, which blocks the interaction between IL-18 binding protein and IL-18. The company has collaboration agreement with Bayer Pharma AG for the research, development, and commercialization of antibody-based therapeutics against the company's immune checkpoint regulators; Bristol-Myers Squibb to evaluate the safety and tolerability of COM701 in combination with Bristol-Myers Squibb's PD-1 immune checkpoint inhibitor Opdivo in patients with advanced solid tumors; and Johns Hopkins School of Medicine to evaluate novel T cell and myeloid checkpoint targets. It has license agreement with AstraZeneca for the development of bi-specific and multi-specific immuno-oncology antibody products; and research collaboration with Johns Hopkins University for myeloid. Compugen Ltd. was incorporated in 1993 and is headquartered in Holon, Israel.
help-icon Live chat